Abstract
Vaccination protocols based on targeting of the idiotype expressed on malignant B cells have so far provided encouraging results in clinical trials. The essential requirement to induce an immune response is the inclusion of carriers to overcome T-cell tolerance. Chemical cross-linking of idiotypic protein is so far the method of choice to induce protective responses in human studies. Meanwhile, a flurry of alternative strategies to simplify vaccine production is being tested in murine model. Thanks to the advance in antibody engineering the two relevant antigenic domains of the lymphoma immunoglobulin can be assembled into an appropriate format, genetically linked to molecules that act as immunological adjuvants and directly delivered as plasmid DNA. Upon immunization, rejection of tumor cells may depend on cellular or humoral mechanisms, whose relative importance has not been entirely estimated. We have recently analyzed the specificity of anti-idiotypic antibodies induced by DNA vaccination and cha racterised the elements contributing to optimal anti-idiotypic responses.
Keywords: Genetic Vaccination, B-Cell Malignancies, LYMPHOMA, Dendritic cell
Current Gene Therapy
Title: Genetic Vaccination for the Immunotherapy of B-Cell Malignancies
Volume: 2 Issue: 2
Author(s): F. Benvenuti and O. R. Burrone
Affiliation:
Keywords: Genetic Vaccination, B-Cell Malignancies, LYMPHOMA, Dendritic cell
Abstract: Vaccination protocols based on targeting of the idiotype expressed on malignant B cells have so far provided encouraging results in clinical trials. The essential requirement to induce an immune response is the inclusion of carriers to overcome T-cell tolerance. Chemical cross-linking of idiotypic protein is so far the method of choice to induce protective responses in human studies. Meanwhile, a flurry of alternative strategies to simplify vaccine production is being tested in murine model. Thanks to the advance in antibody engineering the two relevant antigenic domains of the lymphoma immunoglobulin can be assembled into an appropriate format, genetically linked to molecules that act as immunological adjuvants and directly delivered as plasmid DNA. Upon immunization, rejection of tumor cells may depend on cellular or humoral mechanisms, whose relative importance has not been entirely estimated. We have recently analyzed the specificity of anti-idiotypic antibodies induced by DNA vaccination and cha racterised the elements contributing to optimal anti-idiotypic responses.
Export Options
About this article
Cite this article as:
Benvenuti F. and Burrone R. O., Genetic Vaccination for the Immunotherapy of B-Cell Malignancies, Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605654
DOI https://dx.doi.org/10.2174/1566523024605654 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab
Current Drug Safety Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Advances and Application of DNA-functionalized Nanoparticles
Current Medicinal Chemistry New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Current Signal Transduction Therapy Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer
Current Drug Targets Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Identification of Novel Drug Targets in HpB38, HpP12, HpG27, Hpshi470, HpSJM180 Strains of Helicobacter pylori : An In Silico Approach for Therapeutic Intervention
Current Drug Targets Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Protective Effects of Low Dose Vorinostat on Cisplatin-Induced Nephrotoxicity in Rats
Current Molecular Pharmacology Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Current Medicinal Chemistry The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Cell Arrest and Apoptosis Induced by the Next Generation of Vanadium Based Drugs: Action Mechanism to Structure Relation and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Marine Microbes-Derived Anti-Bacterial Agents
Mini-Reviews in Medicinal Chemistry Discovery of Modulators of Protein-Protein Interactions: Current Approaches and Limitations
Current Topics in Medicinal Chemistry Proliferative Activity Of Neokyotorphinrelated Hemoglobin Fragments In Cell Cultures
Protein & Peptide Letters